



Biotech Daily

Thursday September 10, 2026

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ATOMO, MICRO-X, PARADIGM UP 6%
- ARTRYA DOWN 19%**
- * **OPTISCAN: AUSTRALIAN CLINICAL LABS IMAGE 84 SAMPLES**
- * **NEURIZON REDEEMS 1m OBSIDIAN NOTES**
- * **MONASH OFFERS DOCTOR OF PHARMACY FROM 2027**
- * **BCAL DENIES MERGER TALKS WITH GENETIC SIGNATURES, MICROBA**
- * **AUSBIOTECH GOLD COAST CONFERENCES NEXT MONTH**
- * **EMYRIA INVITED TO FDA PSYCHEDELICS HEARING**
- * **CLEO: ASURAGEN TO VALIDATE PRE-SURGICAL OVARIAN CANCER TEST**
- * **MARK BOUW REPLACES TISSUE REPAIR CFO DION COHEN**

MARKET REPORT

The Australian stock market fell 1.03 percent on Thursday September 10, 2026, with the ASX200 down 92.0 points to 8819.4 points. Seven of the Biotech Daily Top 40 companies were up, 28 fell, four traded unchanged and one was untraded. The four Big Caps were mixed.

Micro-X was the best, up 0.1 cents or 5.9 percent to 1.8 cents, with 2.0 million shares traded; followed by Atomo and Paradigm, both up 5.6 percent to 1.9 cents and 28.5 cents, respectively, with 269,122 shares traded and 6.3 million shares traded, respectively. Optiscan climbed 3.3 percent; Alcidion rose 2.5 percent; Cochlear was up 1.7 percent; with 4D Medical, Pro Medicus and Telix up by less than one percent.

Artrya led the falls, on no news, down 77 cents or 19.15 percent to \$3.25, with 2.4 million shares traded.

Impedimed lost 16.7 percent; Lumos was down 9.1 percent; Amplia and Imugene fell more than seven percent; EBR was down 6.8 percent; Botanix and Clarity were down five percent or more; Cyclopharm, Emvision, Immutep, Imricor and Polynovo fell four percent or more; Dimerix, Nova Eye, Proteomics, Racura and Starpharma were down more than three percent; Mesoblast, Nanosonics and Saluda shed more than two percent; with Actinogen, Aroa, Avita, Clinuvel, Compumedics, CSL, Medical Developments, Neuren and Resmed down by one percent or more.

OPTISCAN IMAGING

Optiscan says it has imaged 84 cases in its digital pathology study with Australian Clinical Labs, using its Inform point-of-care, digital microscope and viewing technology platform. Optiscan said the study was conducting “slide-free cellular imaging at the point of contact, in a real-world pathology environment” to evaluate the Inform system.

The company said that the study was at Australian Clinical Labs anatomical pathology laboratory in Western Australia and was generating pathology data to support workflow optimization, pathologist training and regulatory submissions.

Optiscan said that with Australian Clinical Labs it was “able to validate the technology across a diverse range of tissue types, cancers, and clinical use cases”.

The company said the human tissue cases assessed included breast, head and neck, gastro-intestinal, urinary, reproductive, respiratory, cardiovascular, endocrine, kidney, liver, prostate, eye, and skin; as well as pathologies such as normal, benign, inflammatory, pre-malignant, and malignant.

Optiscan said that as samples from different organs and disease states moved through the laboratory, the device captured digital, cellular-level images that pathologists evaluated against conventional pathology methods such as standard haematoxylin and eosin-stained glass slides to assess image quality and clinical performance.

The company said that Australian Clinical Labs was “one of the country's largest providers of hospital-based pathology services, ... [offering] access to an established pathology ecosystem capable of accelerating validation activities and refining how Inform integrates into existing laboratory workflows”.

Optiscan said that “passing the 80-case milestone represents an important step in [its] strategy to establish Optiscan Inform within leading clinical pathology environments”.

The company said the program expanded its understanding of how the Inform microscope and viewing system would be applied across a broader range of tissue types and pathology workflows, strengthening the platform's long-term scalability and commercial appeal; and provided “an important evidence base to support future regulatory submissions in Australia and the US”.

Optiscan said that showing how Inform performed “within an active anatomical pathology laboratory provides the company with the opportunity to optimize the platform for routine clinical use before commercial rollout ... [and] established a reference site ... which will provide critical support to future commercial discussions, and position Optiscan for broader adoption of its digital pathology technologies”.

Optiscan managing-director Prof Camile Farah told Biotech Daily that “none of the other digital microscopes were point-of-care”.

Prof Farah told the ASX “imaging more than 80 cases ... is an incredible achievement”.

“This milestone doesn't just demonstrate the maturity and commercial readiness of our Inform platform, it also highlights the potential impact real-time cellular imaging can have in transforming pathology,” Prof Farah said.

“Results to date from the ... study have materially advanced the clinical validation of our technology, particularly in terms of evaluating how Inform performs across a range of tissue types and disease settings,” Prof Farah said. “Inform has been able to generate high resolution images of all soft tissue cancer types evident in the study's first 84 cases, recapitulating standard ...stained glass slide detail.”

“For us, this isn't just about testing a device, it's about understanding how the technology may perform in the hands of pathologists and pathology technicians during their everyday work,” Prof Farah said. “Digital pathology is rapidly reshaping the way tissue is analyzed, and the collaboration ... gives Optiscan the opportunity to be part of this process”.

Optiscan was up half a cent or 3.3 percent to 15.5 cents.

NEURIZON THERAPEUTICS

Neurizon says it will redeem 1,000,000 convertible notes held by Obsidian, leaving 750,000 notes outstanding.

Neurizon said that the notes had a face value of \$US1,110,000 (\$A1,537,000) and would be redeemed for \$US1,150,000.

The company said that as part of the agreement, Obsidian agreed not to sell Neurizon shares for two months.

Separately, in an 'Application for quotation of securities' Neurizon said the purpose was the "conversion of 250,500 convertible notes with face value of \$385,224.44 by Obsidian Global GP, at a conversion price of 5.18 cents per note, under the convertible note facility" Last year, Neurizon said it had a \$20 million convertible note facility with New York's Obsidian Global GP to fund its 'Healey' ALS platform trial (BD: Jan 18, 2026).

Last year, the company said "the investor may reduce the aggregate number of placement shares by a number of shares by ... paying the company for the relevant number of shares, the price being the amount equal to the number of shares multiplied by 94 percent of the average of the lowest five daily [volume-weighted average price] during the 20 actual trading days prior to the date of the notice, rounded to the nearest 0.01 cents".

The company said that "reducing Obsidian's holding of convertible notes on improved terms, together with the agreed standstill, is in the best interests of shareholders".

Interim executive chair Sergio Duchini said the redemption was "part of an active and disciplined approach to capital management".

"The board considers securing an improved premium on the redemption, together with Obsidian's agreement to not sell Neurizon shares for two months reflects an appropriate and considered allocation of shareholder funds," Mr Duchini said.

Neurizon fell 0.7 cents or 2.5 percent to \$2.75 with 902,209 shares traded.

MONASH UNIVERSITY

Monash University says it will offer Victoria's only Doctor of Pharmacy degree from next year at its Faculty of Pharmacy and Pharmaceutical Sciences.

Monash University said that the five-year Bachelor of Pharmacy (Honors) and Doctor of Pharmacy double degree had been "designed to meet new Australian entry-to-practice standards, focusing on clinical decision-making, person-centred care, cultural safety, sustainability and digital literacy, including responsible [artificial intelligence] use".

The University said that in the final year of the program, students would "undertake an accredited intern training program, alongside paid supervised practice in a hospital or community pharmacy while completing electives that align with new and emerging roles for pharmacists in Australia".

The University said students could complete a Bachelor of Pharmacy (Honors) in four years, or a Master of Pharmacy after five years, with a reduced workload in the fifth year. Monash Pharmacy and Pharmaceutical Sciences student and president of the National Australian Pharmacy Students' Association, Mia Avram, said the program's structure addressed "the practical realities of modern pharmacy".

"With pharmacists taking on expanded roles in areas like prescribing and aged care, it's important as students that our education keeps pace with these changes and prepares us for the realities of practice," Ms Avram said.

"Completing the final year alongside a paid internship gives students the opportunity to learn in the classroom while simultaneously developing their skills in practice, helping to bridge the gap between university and the profession," Ms Avram said.

For more information, go to: <https://www.monash.edu/pharm/future/courses/pharmacy>.

BCAL DIAGNOSTICS, GENETIC SIGNATURES, MICROBA LIFE SCIENCES

Bcal says it has not made or received any proposal and is not in discussions with Genetic Signatures or Microba Life Sciences regarding, a merger or other combination.

Bcal said “no such proposal has been considered by the Bcal board”.

The company said comments in a newspaper article attributed to David Williams of Kidder Williams, which advises Bcal in relation to its investment in Genetic Signatures, “refer to the views of some fund managers who have been advocating for a three-way merger”.

“These comments were not made on behalf of, or with the authority of Bcal,” Bcal said.

Bcal said “scale is important to the long-term success of Australian diagnostics companies ... [and] consistent with that view, Bcal continues to assess opportunities that it considers may create value for its shareholders”.

The company said that “nothing in this announcement should be taken as precluding Bcal from consideration of any proposal or transaction in the future”.

Two weeks ago, Bcal said that it had increased its holding in Genetic Signatures to 41,923,644 shares (18.46%) and said that it saw Genetic Signatures “as a highly complementary molecular diagnostics company ... [and the] strategic rationale for this investment is to broaden and diversify Bcal’s diagnostic platform into infectious diseases, leveraging complementary technical capabilities and laboratory facilities, as well as expanded distribution opportunities” (BD: Aug 26, 2026).

On the same day, Genetic Signatures said it was in discussions with Microba to assess a potential merger to establish “a leading, scalable, ASX-listed infectious disease diagnostics group”.

Bcal was up 1.1 cents or 16.9 percent to 7.6 cents.

Genetic Signatures was up 0.3 cents or 3.85 percent to 8.1 cents.

Microba was untraded at 5.6 cents.

AUSBIOTECH

Ausbiotech says it will hold its Ausbiotech, Ausbiotech Invest and Ausmedtech, conferences from October 21 to 23, 2026 on the Gold Coast, Queensland.

In May, Ausbiotech said it would align its conferences into one “umbrella platform” called ‘Australia’s Biggest Week in Biotech’ (BD: May 29, 2026).

The organization said each conference would retain its own purpose and Ausmedtech would “remain the dedicated conference for Australia’s [medical technology] sector”.

Ausbiotech said that the Invest meeting would “continue as our standalone premier investment event with its own venue, registration pass, and dedicated program”.

Ausbiotech said its conference and Ausmedtech would be delivered as “a connected program experience, allowing delegates to move across sessions and engage more broadly across Australia’s life sciences ecosystem through a single registration pass”.

Ausbiotech said that Synthesis Bioventures managing-director Prof Andrew Wilks would deliver the Prof Nancy Millis Oration, sponsored by CSL, and described as “one of the biotech industry’s most respected honors” (BD: Aug 20, 2025).

The industry organization said that Burns Service of Western Australia director and founder of Clinical Cell Culture (now Avita Medical) Prof Fiona Wood would deliver the Sanofi-sponsored Dr Irene Depaz Oration.

Ausbiotech said the program had more than 250 speakers in about 60 sessions, “bringing together ... leaders from across biotechnology, medical technology, health technology, investment, research, and government”, with 2,000 attendees expected.

Ausbiotech said the conferences would be held at the Gold Coast Convention and Exhibition Centre, with registration at: <https://biggestweekinbiotech.com/register/>.

EMYRIA

Emyria says it has been invited by the US Food and Drug Administration to deliver in-person remarks at an FDA public hearing on September 14, 2026.

Emyria said the hearing into 'Considerations for Potential Future Therapeutic Use of Psychedelic Drugs' would be held at the FDA's White Oak Campus in Silver Spring, Maryland and from 12:30pm to 4:30pm (USET).

The company said the FDA was "convening the hearing to obtain perspectives on the potential future therapeutic use of psychedelic drug products in supervised and supportive settings, including practical considerations relevant to safe, effective and scalable treatment delivery".

Emyria said the selection gave it "an opportunity to contribute real-world Australian treatment delivery experience to a US Federal discussion examining the potential future delivery of psychedelic medicines targeting an audience which comprises regulatory authorities, drug sponsors, providers and other relevant stakeholders".

Emyria was unchanged at 4.8 cents with nine million shares traded.

CLEO DIAGNOSTICS

Cleo says the Clinical Laboratory Improvement Amendments (CLIA) certified Asuragen will conduct clinical validation of its pre-surgical ovarian cancer test.

Cleo said that the Austin Texas-based Asuragen was the CLIA laboratory of the Minneapolis, Minnesota-based Bio-Techne Corp.

The company said the engagement strengthened its "strategic relationship with Bio-Techne, integrating commercial test kit manufacture, the Ella diagnostic platform, and execution of ... [its] US clinical testing program through Asuragen".

Cleo said the appointment followed the receipt of the first production batch of test kits from Bio-Techne (BD: Sep 3, 2026).

The company said the program would generate clinical performance data, including sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).

Cleo said that the results of the program would form the core evidence base supporting its planned US Food and Drug Administration FDA 510(k) submission, which it hoped to file by July 2027.

Cleo was unchanged at 34 cents.

TISSUE REPAIR

Tissue Repair says that Mark Bouw will replace Dion Cohen as its chief financial officer effective from today.

Tissue Repair said that Mr Bouw was the founder and chief executive officer of advisory firm Straterra Australia, with more than 30 years of experience in clinical practice, finance leadership and was previously a director of Volpara Health Technologies.

According to his LinkedIn page Mr Bouw held a Bachelor of Applied Science in Nursing from Geelong's Deakin University and a Master of Business Administration from the University of Sydney.

The company said it thanked Mr Cohen for his services.

Tissue Repair was untraded at 8.0 cents.